amyloidosis is the second most common form of the disease worldwide. With its associated chronic
inflammatory diseases (e.g., rheumatoid arthritis, Crohn’s disease, and familial Mediterranean fever), amyloid deposition is very gradual. The survival rate is often more than 10 years, particularly with treatment for kidney disease. In contrast, untreated infections such as osteomyelitis or tuberculosis can cause a quicker accumulation of amyloid
In all cases, the mainstay of therapy is to address the underlying infection or inflammatory condition. This can slow or stop the progressive buildup of amyloid by reducing the circulating precursor protein, serum amyloid A. Moreover, an oral drug called eprodisate (Kiacta) has been found to inhibit the formation of amyloid fibrils. Kiacta prevents serum amyloid A from interacting with other molecules